Intellia Therapeutics Inc. (NASDAQ: NTLA) on Thursday released longer-term follow-up data from the ongoing Phase 1 study of investigational nexiguran ziclumeran (nex-z) for the treatment of hereditary ATTR amyloidosis with polyneuropathy (ATTRv-PN).Results were presented at the International ATTR Amyloidosis Annual Meeting for Patients and Doctors. The results were simultaneously published in the New England Journal of Medicine.DataDeep, durable and consistent TTR reductions continue to be observed. Across ...

One dose of nex-z led to rapid, deep and durable TTR reductions, with mean reductions of at least 90% from baseline sustained through three yearsStabilization or improvement in disease-related clinical measures observed at 24 monthsContinue to observe generally favorable safety data with no new drug-related events within the follow-up periodData presented today at the 5th International ATTR Amyloidosis Annual Meeting for Patients and Doctors with simultaneous publication in the New England Journal of Medici ...

Longer-term data to be presented at the 5th International ATTR Amyloidosis Meeting for Patients and Doctors on September 25 highlighting up to three years of patient follow-up and additional insight into ATTRv-PN disease-relevant measuresCAMBRIDGE, Mass., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that longer-term data from the ongoing Phase 1 tria ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?My Buy call on Intellia Therapeutics, Inc. (NASDAQ: NTLA ) stock made in a Seeking Alpha post published last month—August 15th, to be precise—has already paid off. Shares have been soaring in value thisThe group is ...

If you are interested in keeping up to date with stocks making moves within the biotech, pharma and healthcare industries, and understanding the key trends and catalysts driving valuations ahead of the market, why not subscribe to my weekly newsletter via my Investing Group, Haggerston BioHealth ?My Buy call on Intellia Therapeutics, Inc. (NASDAQ: NTLA ) stock made in a Seeking Alpha post published last month—August 15th, to be precise—has already paid off. Shares have been soaring in value thisThe group is ...

股价表现 - Intellia Therapeutics股价昨日飙升29.8% 因完成关键研究患者招募[1] - 公司年初至今股价上涨38.2% 远超行业3.3%的涨幅[5] 核心产品lonvoguran ziclumeran (lonvo-z)进展 - 已完成III期HAELO研究患者招募 该研究针对遗传性血管性水肿治疗[1] - 研究主要终点包括血管性水肿发作次数及治疗后第5-28周无发作患者比例[6] - 从首例患者给药到完成招募仅用9个月时间[7] - 预计2026年上半年获得顶线数据 2026年下半年提交生物制剂许可申请[2][8] - 若获批准 计划2027年上半年在美国上市[2] - 通过抑制血浆激肽释放酶活性预防血管性水肿发作[9] 另一候选产品nexiguran ziclumeran (nex-z)进展 - 与Regeneron合作开发 后者承担25%开发成本并分享商业利润[10] - 针对ATTRv-PN和ATTR-CM两种适应症[11] - III期MAGNITUDE研究(ATTR-CM)正在招募患者[11] - 2025年4月启动ATTRv-PN的III期MAGNITUDE-2研究 预计2026年上半年完成招募[11] - 阳性数据将支持全球监管申报[12] 行业比较 - Akero Therapeutics2025年每股亏损预期从3.93美元收窄至3.74美元 股价年初至今上涨66.1%[14] - Adaptive Biotechnologies2025年每股亏损预期从0.87美元收窄至0.71美元 股价年初至今上涨129.6%[15]

Intellia Therapeutics, Inc. (NTLA) shares ended the last trading session 29.8% higher at $16.11. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 21.6% gain over the past four weeks.The stock rallied after the company announced that it has completed enrollment in the pivotal phase III HAELO study evaluating its investigational candidate, lonvoguran ziclumeran (lonvo-z) for treating patients with hereditary angioedem ...

Completed patient enrollment within nine months with nearly half enrolled from the U.S.Expect to report Phase 3 topline data in the first half of 2026On track to submit BLA in the second half of 2026 for an anticipated U.S. launch in the first half of 2027Plan to present additional data from the Phase 1/2 study in the fourth quarter of 2025 CAMBRIDGE, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing ...

核心观点 - 通过识别具有1000%上涨潜力的股票来构建财富 这些投资能将10万美元变成100万美元或将1000万美元投资组合变成1亿美元[1] - Apogee量化系统寻找符合"下跌很多 上涨一点"模式的高质量股票 并应用多个"10倍因子"来识别潜在1000%回报的投资机会[3][20][21] - 系统聚焦于具有优秀基本面但股价因外部因素下跌的中大型公司 类似抛售后的英伟达和苹果 风险低于预期[5] 钛白粉行业 - Tronox Holdings是全球最大钛白粉(TiO2)生产商之一 钛白粉是油漆 润滑剂和牙膏中使用的白色颜料 没有替代品[2] - 当前钛白粉价格处于下行周期但最终将逆转 推动Tronox股价回到20美元区间 意味着4倍回报 自推荐以来股价已上涨25%[3] 基因编辑疗法 - Intellia Therapeutics股价从2021年峰值202美元下跌97%至5.90美元历史低点 符合"下跌很多 上涨一点"标准[7][8] - Ionvo-z药物治疗遗传性血管性水肿 影响全球约5万人中的1人 三期数据显示10名患者病情改善98% 预计2028年上市 峰值销售额可达10亿美元[9] - Nex-z药物治疗遗传性转甲状腺素蛋白淀粉样变性 在某些人群中发病率达1/20 预计2029年上市 年销售额潜力达20亿美元[10] - 两种药物获批概率分别为35%和40% 若成功 Intellia估值可达100-150亿美元 较当前12亿美元市值有1220%上涨空间[11] - Regeneron制药承担25%的nex-z项目开发和利润分成 并提供商业化路径[11] 中国自动驾驶行业 - 中国汽车市场经过激烈竞争 车型比美国更便宜 更快 更好 小米SU7 Ultra售价73,000美元 提供1,500马力[13][14] - 中国街道上的自动驾驶出租车数量已超过美国 预计到2030年将达到400万辆 较目前增长1600倍[14] - WeRide是中国最大纯机器人出租车公司 由百度前自动驾驶首席科学家创立 中国第二大机器人出租车服务提供商[15][16] - 与博世合作开发端到端高级驾驶辅助系统(ADAS) 有望成为一级汽车零部件供应商[16] - 股价从年初低点上涨60% 此前下跌86% 符合"下跌很多 上涨一点"模式[17] - 积极向中东和欧洲扩张 26亿美元估值有1000%上涨潜力[18] 成功案例 - Apogee系统已识别出多个具有1000%上涨潜力的公司[3] - 历史成功案例包括TotalEnergies上涨1489% Adidas上涨1622% Westpac Banking上涨5941%[23]

投资策略 - 专注于投资具有颠覆性潜力的早期技术公司 即使产品尚未上市或收入流处于早期阶段[2] - 利用股价下跌机会增持看好的股票 旗舰基金Ark Innovation过去一年上涨超过80%[1] - 近期增持两家基因编辑领域生物技术公司 华尔街预测这两家公司未来12个月将大幅上涨[3] CRISPR Therapeutics公司进展 - 专注于CRISPR基因编辑技术 通过切割特定DNA位点修复致病基因[5] - 首款产品Casgevy获批准用于治疗镰状细胞病和β地中海贫血 这是近两年前的重要里程碑[6] - 已启动75个治疗中心 完成115例患者细胞采集 治疗过程包含细胞采集、编辑和回输多个步骤[7] - 拥有17亿美元现金储备 财务实力雄厚 支持肿瘤学和自身免疫疾病领域的多个临床阶段候选药物[8] - 股价较2025年7月高点下跌20% 华尔街预测未来12个月可能上涨50%[9] Intellia Therapeutics公司进展 - 开发CRISPR基因编辑候选药物 晚期项目与CRISPR Therapeutics针对不同疾病领域[10] - 最接近上市的是NTLA-2002(Lonvo-z) 用于治疗遗传性血管性水肿(HAE) 计划2025年下半年提交监管申请[12] - HAE治疗在早期试验中显示月发作率平均降低98% 这是经过三年随访期的数据[11] - 同时推进转甲状腺素蛋白淀粉样变性基因编辑项目的晚期研究[12] - 拥有超过6.3亿美元现金 预计可支持运营至2027年上半年并完成首款产品上市[12] - 华尔街极度看好 平均12个月股价预测暗示190%的惊人涨幅[13]